Method of treating pruritus with IL-31 monoclonal antibodies
First Claim
Patent Images
1. A method of treating pruritus in a mammal comprising administering to the mammal a therapeutically effective amount of a monoclonal antibody that specifically binds to human IL-31, wherein the monoclonal antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 44, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO;
26.
0 Assignments
0 Petitions
Accused Products
Abstract
The invention provides humanized mouse anti-human IL-31 antibodies and antibody fragments that are capable of binding IL-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of IL-31.
116 Citations
28 Claims
-
1. A method of treating pruritus in a mammal comprising administering to the mammal a therapeutically effective amount of a monoclonal antibody that specifically binds to human IL-31, wherein the monoclonal antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 44, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO;
26. - View Dependent Claims (2, 3, 4, 5, 6, 7)
- 44, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO;
-
8. A method of treating pruritus in a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a monoclonal antibody that specifically binds to human IL-31 and a pharmaceutically acceptable carrier, wherein the monoclonal antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 44, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO;
26. - View Dependent Claims (9, 10, 11, 12, 13, 14)
- 44, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO;
-
15. A method of treating a pruritic disease in a mammal comprising administering to the mammal a therapeutically effective amount of a monoclonal antibody that specifically binds to human IL-31, wherein the monoclonal antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 44, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO;
26, and wherein the pruritic disease is selected from the group consisting of atopic dermatitis, contact dermatitis, dermatitis, prurigo nodularis, eczema, vitiligo, alopecia aerata, acne rosacea, acne vulgaris and bullous pemphigoid. - View Dependent Claims (16, 17, 18, 19, 20, 21)
- 44, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO;
-
22. A method of treating a pruritic disease in a mammal comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition comprising a monoclonal antibody that specifically binds to human IL-31 and a pharmaceutically acceptable carrier, wherein the monoclonal antibody comprises a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:
- 44, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO;
26, and wherein the pruritic disease is selected from the group consisting of atopic dermatitis, contact dermatitis, dermatitis, prurigo nodularis, eczema, vitiligo, alopecia aerata, acne rosacea, acne vulgaris and bullous pemphigoid. - View Dependent Claims (23, 24, 25, 26, 27, 28)
- 44, and a light chain variable domain comprising the amino acid sequence of SEQ ID NO;
Specification